Loss of CDKN2A/2B is observed in up to 35 % of DLBCL-NOS patients and is significantly associated with a poor prognosis after R-CHOP treatment, independently of the international prognostic index (IPI) and COO [120]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.